FibroGen sells China unit to AstraZeneca for $160m
AstraZeneca has agreed to acquire FibroGen’s China subsidiary for approximately $160m, securing full control over the anaemia drug roxadustat in …
Post
-
-
Zealand Pharma steadfastly upholds amylin-based obesity drug strategy
Zealand Pharma’s search for a partner for its amylin-based obesity therapy petrelintide remains ongoing, with no agreement announced in its …
-
X4 and taiba to distribute WHIM syndrome therapy in Middle East
US-based X4 Pharmaceuticals has entered an exclusive agreement with United Arab Emirates (UAE)-based pharmaceutical products wholesaler taiba rare to distribute …
-
Key pharma launch trends in 2024
Drug manufacturers faced a variety of hurdles in 2024. Healthcare system reforms, preparation for the EU joint clinical assessments (JCAs) …
-
WHO targets over half a million children in Gaza for polio vaccine drive
The World Health Organization (WHO) said it will conduct another mass vaccination round in the Gaza Strip to protect children …
-
FDA authorises ImmunityBio’s BCG alternative to treat bladder cancer
ImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an alternative source …
-
Pharma and medtech industry reacts to FDA, CDC and NIH job cuts
Figures from across the pharmaceutical and medtech industry have spoken out on social media following the culling of staff at …
-
FDA grants priority review for Boehringer’s zongertinib NDA in NSCLC
The US Food and Drug Administration (FDA) has granted priority review to Boehringer Ingelheim’s new drug application (NDA) for zongertinib …
-
Scientists develop largest ever biological AI model that ‘thinks in nucleotides’
A team of US scientists has developed a new foundation model that can sift through genetic code across biology's five …
-
Supernus’s stock sinks after depression drug fails trial
Supernus Pharmaceutical’s stock declined following the release of disappointing Phase IIb trial results for SPN-820, an investigational treatment for adults …
-
Sanofi moves closer to selling controlling stake in $17bn-valued Opella
Sanofi’s sale of its $17bn consumer health business Opella just advanced a step closer, after the drugmaker signed a share …
-
Cumberland’s Vibativ injection gains China’s NMPA approval
Cumberland Pharmaceuticals' antibiotic Vibativ (telavancin) injection has gained approval from China’s National Medical Products Administration (NMPA), offering a new treatment …
-
Amazon joins forces with Memorial Sloan Kettering for AI-powered drug discovery
Amazon Web Services (AWS) and US-based Memorial Sloan Kettering Cancer Center (MSK) have announced a partnership to leverage artificial intelligence …
-
GLP-1RAs and opioid use disorder: a new frontier in addiction treatment
Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s tirzepatide (Mounjaro, Zepbound) have dominated headlines …
-
Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment
Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet syndrome in all …
